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A Novel Domain in AMP-Activated Protein Kinase
Causes Glycogen Storage Bodies Similar to Those
Seen in Hereditary Cardiac Arrhythmias
AMPK homologs from all eukaryotes contain an “N-iso-
amylase” domain, which is located between residues
72 and 151 in rat 1. These noncatalytic domains are
found in a variety of other proteins, most of which are
enzymes that metabolize the 1→6 branches in 1→4
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In order to define the minimal region of the 1 subunit1-5-45 Yushima
Bunkyo-ku, 113-8549 required for formation of the AMPK complex, we made
a series of truncations and expressed them, along withJapan
myc-tagged 1 and 1, in CCL13 cells. Lysates were
precipitated with anti-myc antibody, and kinase activity
was measured (Figure 1B). As demonstrated previouslySummary
[10], no activity was obtained unless a  subunit was
coexpressed. Surprisingly, if a 1 subunit (64–270) withThe AMP-activated protein kinase (AMPK) is an 
heterotrimer that is activated by low cellular energy an N-terminal truncation that removed the poorly con-
served N-terminal region was expressed, the activitystatus and affects a switch away from energy-requir-
ing processes and toward catabolism [1]. While it is increased 5-fold over the full-length construct. The ex-
planation for this is not clear, although it may be relatedprimarily regulated by AMP and ATP, high muscle gly-
cogen has also been shown to repress its activation to the 4-fold increase in activity observed when a non-
myristylatable (G2A) mutant of 1 was coexpressed with[2, 3]. Mutations in the 2 and 3 subunit isoforms
lead to arrhythmias associated with abnormal glyco- 1 and 1 in COS-7 cells [11]. Constructs that had lost
all or part of the GBD/KIS domain (113–270, 167–270,gen storage in human heart [4–7] and elevated glyco-
gen in pig muscle [8], respectively. A putative glycogen 172–270, and 196–270) had activities that were similar
to, or moderately depressed (50%), compared withbinding domain (GBD) has now been identified in the
 subunits. Coexpression of truncated  subunits full-length 1. However, even small C-terminal trunca-
tions of the ASC domain (64–243 and 64–257) causedlacking the GBD with  and  subunits yielded com-
plexes that were active and normally regulated. How- a complete loss of activity. All of the active complexes
(including 196–270) were activated to the same extentever, coexpression of and with full-length caused
accumulation of AMPK in large cytoplasmic inclusions (3- to 4-fold) by AMP, were activated 10- to 20-fold
by incubation with MgATP and the upstream kinase,that could be counterstained with anti-glycogen or
anti-glycogen synthase antibodies. These inclusions AMPKK, and were also activated by incubation of intact
cells for 16 hr with 10 mM metformin. These results (notwere not affected by mutations that increased or abol-
shown) indicate that the known regulatory mechanismsished the kinase activity and were not observed by
are not apparently affected by the absence of the GBD.using truncated  subunits lacking the GBD. Our re-
To confirm that the N-terminally truncated  subunitssults suggest that the GBD binds glycogen and can
lacking the GBD/KIS domain still formed a heterotrimericlead to abnormal glycogen-containing inclusions
 complex, myc-tagged 1 was coexpressed with 1when the kinase is overexpressed. These may be re-
and various truncated 1 constructs in cells incubatedlated to the abnormal glycogen storage bodies seen
with 35S-labeled amino acids. AMPK complexes werein heart disease patients with 2 mutations.
precipitated with anti-myc antibody and were analyzed
by SDS-PAGE and autoradiography (Figure 2A) or byResults and Discussion
probing blots with anti-1, -1, and -1 antibodies (Fig-
ures 2B–2D). A 35S-labeled polypeptide correspondingAccording to the PFAM database (www.sanger.ac.uk/
to myc-1 (migrating just ahead of endogenous c-myc)Software/Pfam/, entry PF02922), the  subunits of
was detected in all cases, except when no 1 vector
had been transfected. The latter was expected because*Correspondence: d.g.hardie@dundee.ac.uk
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Figure 1. Domain Organization of AMPK and the Effect of  Subunit
Truncations on Activity
(A) Domain map of the 1 subunit of AMPK and of the truncated Figure 2. Truncated  Subunits Lacking the GBD Still Form Hetero-
mutants used in this study. The N-isoamylase/glycogen binding trimeric Complexes
domain (GBD) and the KIS and ASC domains [9] are indicated.
(A) 35S-labeled CCL13 cells expressing myc-tagged 1, 1, and full-
(B) Activities of the full-length and truncated 1 mutants when coex-
length or truncated 1 were lysed and immunoprecipitated with
pressed with myc-1 and -1 in CCL13 cells. Proteins were immuno-
anti-myc antibody; half the precipitate was analyzed by SDS-PAGE,
precipitated with anti-myc antibody, and kinase activity was mea-
blotting, and autoradiography.
sured in the precipitate. Activities are expressed relative to the
(B–D) The remaining half was analyzed in the same way, except that
activity obtained with the full-length 1 subunit (0.10  0.01 nmol/
polypeptides were detected by (B) anti-1, (C) anti-1, or (D) anti-
min/mg lysate protein, mean  SEM, n  3) expressed at the same
1 antibodies. The 1 construct transfected is indicated at the top
time.
in (A); migration of marker proteins is shown on the right, and identifi-
cation of the polypeptides is shown on the left. The method used
in (A) detects endogenous c-myc, which was also visible in untrans-
fected cells (not shown). In (C), the secondary antibody also detects subunit [10]. The same polypeptide was detected with
the light chain of sheep immunoglobulin (Ig light chain) used foranti-1 antibody. A 35S-labeled 1 polypeptide was de-
immunoprecipitation.tected in immunoprecipitates from cells in which full-
length or N-terminally truncated  subunits (1–270,
64–270, and 172–270), but not C-terminally truncated the formation of the  complex and that the ASC
domain alone is sufficient. This contrasts with findings in(64–257) or no  subunit, was expressed. Similar results
were obtained with anti-1 antibody. Finally, 35S-labeled the yeast system, in which Sip2p constructs containing
only the ASC domain failed to yield a two-hybrid interac-1 polypeptides of the expected size (1–270, Mr: 30,500;
64–270, Mr 23,500; 172–270, Mr 11,000) were detected tion with Snf1p [9]. However, in that case, the  subunit
gene (SNF4) had been deleted, and it is possible thatin immunoprecipitates irrespective of whether the ex-
pressed  subunit contained the GBD. They were also in our studies the  subunit was bridging  and  to
form the complex. Our data do not rule out the possibilitydetected with an antibody that recognizes the C termi-
nus of 1. No 1 polypeptide was detected by 35S label- that regions N-terminal to the ASC domain of mamma-
lian  interact with , although clearly this is not neces-ing or with an anti-1 antibody in the anti-myc im-
munoprecipitates from cells in which a C-terminally sary to form a stable, active complex.
We also coexpressed plasmids encoding green fluo-truncated (64–257) or no exogenous  subunit had been
expressed (note that C-terminal truncation might affect rescent protein- (GFP-) or myc-tagged 1 with full-
length 1 or 2 and 1 in CCL13 cells. By using iso-recognition by this antibody).
These results show that the GBD is not necessary for form-specific antibodies, we found that all expressed
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Figure 3. Cytoplasmic Inclusions in Cells Expressing GFP-Tagged AMPK Heterotrimers Contain Glycogen
(A–F) Whole-cell projections of CCL13 cells expressing GFP-1 and -1 with (A–C) 1 or (D–F) 2. Cells were fixed and stained with an anti-
glycogen antibody that was detected with a Texas red-labeled secondary antibody. The pictures display the green channel (GFP; [A] and [D]),
the red channel (Texas red; [B] and [E]), or both channels merged (C and F). The insets at the top-left of each panel show the largest cytoplasmic
inclusion in each cell at higher magnification. The scale bars are in m.
subunits and subunit fusions migrated with the expected 270). However, with constructs lacking either part or all
of the GDB/KIS domain (113–270, 167–170, and 196–size; moreover, in every case, there was a modest in-
crease in kinase activity, ranging from 1.6-fold to 5.3- 270), no cells containing inclusions were observed, even
though several hundred cells expressing GFP were ex-fold, over the endogenous level (Figure S1). Cells ex-
pressing GFP-tagged  subunits with  and  were amined. Thus, the GBD is essential for the formation of
the inclusions. With either 1 or 2, the frequency ofexamined in a wide-field deconvolution microscope. In
a significant proportion of cells, we observed striking transfected cells containing inclusions was not depen-
dent on the kinase activity of the complex. Thus, essen-fluorescent inclusions of ovoid shape in the cytoplasm
(Figures 3 and 4, green color). These were more frequent tially the same frequency was obtained with wild-type
GFP-1 (1: 26%  11%, n 34 fields; 2, 70%  13%,when 2 was overexpressed (70% 13% of transfected
cells, mean  SD for n  34 fields, or 342/484 cells) n  34), with a T172D mutant that activates the kinase
by mimicking phosphorylation (1: 24%  11%, n  36;rather than 1 (26%  11%, n  34, 146/546 cells). In
cells expressing 2, there were 2–16 inclusions per cell, 2, 61%  14%, n 35), or with a D139A/T172D mutant
that removes an aspartic acid essential for kinase activ-with a mean number of 7  4 (n  20), varying in length
from 0.5 to 5 m (mean  1.5  0.9, n  139). In cells ity (1: 16%  7%, n  35; 2, 64%  13%, n  31).
Immunoprecipitate kinase assays confirmed that the ac-expressing 1, there were also 2–16 inclusions per cell
(mean  6  3, n  23) that varied from 0.4 to 5 m in tivities of the T172D mutants were higher than the wild-
type (1, 6.2  0.5-fold, n  2; 2, 5.7  0.7-fold, n length (mean  1.7  1.2, n  90). Identical inclusions
were observed when we coexpressed the  subunits 2), while the D139A/T172D mutants were completely
inactive.with GFP-2 rather than GFP-1, or with 2 or 3 rather
than 1 (not shown). They were not an artifact of the Because the GBD was essential for the generation of
these inclusions, we suspected that they might containGFP tag, because they were also observed when myc-
tagged 1 subunits were expressed and detected with glycogen. We therefore utilized a monoclonal antibody
that recognizes glycogen. Figure 3 shows that the inclu-anti-myc antibodies.
Identical frequencies of inclusions were observed by sions stained with this antibody (red color) and that
staining was much stronger when 2 rather than 1 wasusing full-length (26% 11%) or truncated (27% 12%)
1 constructs that still contained the entire GBD (64– expressed. Staining was not observed if the permeabil-
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Figure 4. Cytoplasmic Inclusions in Cells Expressing GFP-Tagged AMPK Heterotrimers Contain Glycogen Synthase
(A–F) Whole-cell projections of CCL13 cells expressing GFP-1, (A–C) 1, or (D–F) 2 and 1. Cells were fixed and stained with an anti-
glycogen synthase antibody that was detected with a Texas red-labeled secondary antibody. The pictures display the green channel (GFP;
[A] and [D]), the red channel (Texas red; [B] and [E]), or both channels merged (C and F). DNA was stained with 4,6-diamidino-2-phenylindole.
The scale bars are in m.
ized cells were pretreated with -amylase (not shown); were observed more frequently in cells expressing 2
(70%) than 1 (26%) is that CCL13 cells do not appearthis finding confirms that the antibody was detecting
glycogen. Close inspection of the inclusions at high to express endogenous 2 (Figure S1). These cells may
therefore not express appropriate anchoring proteins,magnification (Figure 3, insets) revealed that the GFP
fluorescence and the glycogen staining were granular leading to a higher tendency to form aggregates when
2 complexes are overexpressed.in appearance and did not completely overlap. Since
glycogen synthase colocalizes with glycogen [12], we The boundaries of the KIS domain were not precisely
mapped in the yeast two-hybrid study [9], and the onlyalso utilized an anti-glycogen synthase antibody (Figure
4). Although this antibody (unlike the anti-glycogen anti- portion that is highly conserved across all species corre-
sponds to the GBD. Given that closely related domainsbody) gave a general “speckled” cytoplasmic staining,
particularly in cells expressing 2 (Figure 4E), the signal are found in enzymes that bind and metabolise 1→6
branched glucans, that this domain is not necessary forwas highly enriched in the inclusions.
The cytoplasmic inclusions could also be observed by complex formation but is essential for the formation of
unusual glycogen storage bodies when AMPK is overex-differential interference contrast microscopy, but they
were only apparent in transfected (fluorescent) cells, not pressed (this paper), and that results in a companion
paper [14] show that the isolated GBD binds glycogenin nontransfected cells in the same field. Cryo-immuno-
EM with gold-labeled anti-GFP antibodies revealed that in cell-free assays, we propose that, in the future, the
term KIS (kinase interaction sequence) should be aban-the inclusions appeared as patches of higher electron
density in the cytoplasm. Although membranes were doned and that the term glycogen binding domain
should be used instead.clearly visible in the cells, the inclusions were not mem-
brane limited (Figure S2). What is the normal, physiological function of the GBD?
Firstly, glycogen synthase is phosphorylated and inacti-Glycogen particles studied by conventional osmium/
heavy metal-staining EM techniques appear as “ parti- vated by AMPK in vitro [15] and after AMPK activation
in vivo [3, 16], so the GBD may localize AMPK close tocles” of 20–30 nm (possibly single glycogen molecules
with associated proteins) and “ particles” of 100–150 one of its targets. Secondly, it has recently been shown
that high muscle glycogen represses the activation ofnm, apparently formed from clusters of  particles [13].
Our inclusions (0.5–5 m) may represent aggregates AMPK by AICA riboside in rat muscle [3] or by exercise
in humans [2]. Repression of AMPK activation whenformed between clusters of glycogen particles and over-
expressed AMPK. A possible explanation as to why they glycogen content was high would ensure that glyco-
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Supplemental Datagenolysis and glycolysis (which are regulated indepen-
Supplemental Data including the Experimental Procedures are avail-dently of AMPK) would be used as the initial source
able at http://images.cellpress.com/supmat/supmatin.htm.of ATP under these conditions. Only when glycogen
became depleted would AMPK be activated, thus stimu-
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